So-Hyun Park

Title: So-Hyun Park: Innovator in Double-Targeting Antibody Technology

Introduction

So-Hyun Park is a notable inventor based in Namyangju-si, South Korea. He has made significant contributions to the field of immunology through his innovative work on antibodies. His research focuses on developing therapies that can effectively target and treat immunological diseases.

Latest Patents

So-Hyun Park holds a patent for an "Anti-TNF-α/CXCL10 double-targeting antibody and use thereof." This invention relates to a bispecific antibody that effectively binds to both TNF-α (tumor necrosis factor-alpha) and CXCL10 (C-X-C motif chemokine 10). The antibody is designed to have excellent TNF-α inhibitory activity and osteoclast differentiation inhibitory activity compared to single-targeting antibodies. This composition can be utilized in preventing or treating various immunological diseases.

Career Highlights

So-Hyun Park is associated with Metabolic Engineering Laboratories Co., Ltd., where he continues to advance his research in antibody technology. His work has garnered attention for its potential applications in therapeutic settings.

Collaborations

So-Hyun Park collaborates with notable colleagues, including Heun-Soo Kang and Yeong Wook Song. Their combined expertise contributes to the innovative research being conducted at their laboratory.

Conclusion

So-Hyun Park's contributions to the field of immunology through his patented double-targeting antibody technology highlight his role as a leading inventor. His work promises to enhance treatment options for immunological diseases, showcasing the importance of innovation in medical research.